There are lots of Assay Development Events to choose from…. Why Should You Attend IIR’s?

• New Regulatory Hot Topics not addressed anywhere else, including new   white papers & regulatory clarification on potency assessment criteria, Risk Based FC Evaluation, Use of DoE and ISR for bioanalytical development and more...
• The largest most senior biopharmaceutical faculty with the most global perspectives represented
• The original community for cell based assays and bioanalytical scientists where the niche scientists can network and learn from leaders how to improve assay reliability

• More interactive learning formats that facilitate learning and the sharing of best practices than any other event
• What you need to know now to develop robust and reliable assays in just three days
• Two events in one with specific tracks on BioAnalytical Method Development & Cell Based Assays

Attend the 2010 Keynote Presentations

Regulatory Perspectives on Characterization and CMC Challenges with Antibody-Drug Conjugates
Jun Park,PhD, Division of Monoclonal Antibodies, CDER/FDA

NEW WHITE PAPER: Risk Based Strategies for How to Approach FC Function Evaluation
An Song, PhD, Senior Scientist, Associate Director, GENENTECH

2009 Featured Presentations

Compare and Contrast Validation White Paper Screening Cut Point Calculations
Martin Kane, Associate Director, Process Statistics

A Neuronal Cell-based Assay for Highly Sensitive Detection of Pharmaceutical Preparations of BoNT/A and Patient Neutralizing Serum Antibodies
Eric A. Johnson, Professor, Department of Bacteriology, Food Research Institute, University of Wisconsin, Madison